7
The COVID-19 pandemic has provided many intensivists (and some non-intensivists) several years’ worth of severe ARDS management experience over the course of just a few months. While the challenges have, in places,... Read More
7 Tag: ARDS
7 8
Severe acute respiratory syndrome coronavirus 2/coronavirus disease 2019 frequently induces hypercoagulability with both microangiopathy and local thrombus formation, and a systemic coagulation defect that leads to large... Read More
9
In the midst of the 2009 influenza A H1N1 pandemic, clinicians turned to extracorporeal membrane oxygenation (ECMO) as a strategy to save lives. Based on the H1N1 experience, and the ECMO to Rescue Lung Injury in Severe Acute... Read More
7
This well-illustrated book provides detailed guidance on all aspects of physical examination in patients requiring emergency or intensive care. After an introductory section covering basic principles and the recognition of... Read More
7
Among hospitalized patients 65 years or younger with severe COVID-19, asthma diagnosis was not associated with worse outcomes, regardless of age, obesity, or other high-risk comorbidities. Future population-based studies... Read More
8
Infection with SARS-CoV-2 can result in Coronavirus Disease–19 (COVID-19). While the majority of patients are asymptomatic or have mild disease, approximately 14% develop more severe disease including hypoxemic respiratory... Read More
8
Emerging data suggest a crucial role of endothelial dysfunction during SARS-CoV-2 infection, as a direct target of the virus and inflammatory cytokines as well as the main actor in orchestrating a pro-inflammatory and pro-coagulant... Read More
9
The spectrum of coronavirus disease 2019 (COVID-19) ranges from asymptomatic infection to respiratory failure and death of patients. Severely affected patients may develop a cytokine storm-like clinical syndrome with multi-organ... Read More
10
With great interest we read the article by Convertino et al. discussing potential treatment targets for pharmacological immunomodulation in coronavirus disease 2019 (COVID-19) with acute respiratory distress syndrome (ARDS).... Read More
5
This meta-analysis provides evidence for the differentiation of severe cases of COVID-19 based on laboratory test results at the time of ICU admission. Future well-methodologically designed studies from other populations... Read More
7
Since 1980, Fishman’s Pulmonary Diseases and Disorders has delivered unparalleled coverage of pulmonary medicine and the underlying basic and applied science upon which clinical practice is based. The Fifth Edition,... Read More
10
Older COVID-19 patients with higher APACHE II scores on admission, those who developed AKI grades II or III and/or septic shock during ICU stay had an increased risk-of-death. ICU mortality was 31%. A total of 663 patients... Read More
10
The COVID-19 Handbook: Navigating the Future of Healthcare provides factual, evidence-based information on the coronavirus disease 2019 (COVID-19) pandemic. Presented in a concise PDF format, this valuable COVID-19 resource... Read More
8
In this preliminary study of patients with sepsis and ARDS, a 96-hour infusion of vitamin C compared with placebo did not significantly improve organ dysfunction scores or alter markers of inflammation and vascular injury.... Read More
6
COVID-19 related cardiopulmonary failure such as ARDS and cardiogenic shock or massive pulmonary embolism can be successfully supported with ECMO. Judicious patient selection is important to enable maximal benefit and optimized... Read More
![Between June 18 and Aug 3, 2020, Ministry of Health of the Russian Federation enrolled 76 participants to the two studies (38 in each study). In each study, 9 volunteers received rAd26-S in Phase 1, nine received rAd5-S in phase 1, and 20 received rAd26-S and rAd5-S in Phase 2. Both vaccine formulations were safe and well tolerated. In both Phase 1 and 2 studies of the Sputnik V vaccine all 76 participants developed antibodies to the virus that causes COVID-19. The most common adverse events were pain at injection site (44 [58%]), hyperthermia (38 [50%]), headache (32 [42%]), asthenia (21 [28%]), and muscle and joint pain (18 [24%]). Most adverse events were mild and no serious adverse events were detected. All participants produced antibodies to SARS-CoV-2 glycoprotein. Cell-mediated responses were detected in all participants at day 28, with median cell proliferation of 2·5% CD4+ and 1·3% CD8+ with the frozen formulation, and a median cell proliferation of 1·3% CD4+ and 1·1% CD8+ with the lyophilised formulation. The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile and induced strong humoral and cellular immune responses in participants. Further investigation is needed of the effectiveness of this vaccine for prevention of COVID-19.](https://criticalcare.news/wp-content/uploads/from-russia-with-love-sputnik-v-covid-19-vaccine-generated-an-immune-response-100x100.jpg)
